Compare General Mills, Inc. (GIS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Eli Lilly And Co — how do they compare? General Mills, Inc. trades at $32.05 (market cap $17.43B), while Eli Lilly And Co trades at $1,173.22 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 59.7× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Eli Lilly And Co for 93 Days on average.
| GIS | LLY | |
|---|---|---|
Market Cap | $17.43B | $1.04T |
Volume | 16,554,362 | 3,064,878 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $1.28K |
52-Week Low | $31.67 | $799.57 |
Typical Hold Time | 106 Days | 93 Days |
Enterprise Value | $30.61B | $1.09T |
Dividend Yield | 7.49% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.09, up 1.01% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces fundamental challenges with a negative net income margin of -4.89% and ROE of -10.55% for 2026, though it maintains strong operating cash flow of $2.92B in 2025. Recent leadership transition to Dana McNabb as CEO and a $3B cost-saving initiative aim to stabilize performance amid declining revenues.
The stock presents a value opportunity with a low P/E of 9.23 and a 7.6% upside to the $36 consensus target, supported by a reliable dividend. However, risks include persistent margin pressures, high debt levels at 45% of assets, and competitive headwinds in the packaged foods sector. Analyst sentiment is cautious with 61% hold ratings, reflecting uncertainty around the turnaround strategy's execution.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
